Search Results 271-280 of 13933 for Assay
Feeder layer. In situ chemotaxis assay. Direct preparation. More about research at ...
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early- ...
... assay obtained at baseline. Genotype-Phenotype Correlation in Cardiovascular Disease. Rochester, Minn. This research study is being done to help characterize ...
The purporse of this study is to determine if biomarker assay obtained at ... assay obtained at baseline. . Mayo Clinic Footer. Request Appointment · Give ...
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR). Rochester, Minn. The purpose of this ...
Rochester, Minn. The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, ...
"The power of this gene expression assay is that it allows oncologists to provide personalized assessment of a patient's risk of breast cancer recurrence ...
... assay of salivary melatonin levels, and to examine the impact of low-dose melatonin on SOL and overall sleep quality in patients withcomorbid AUD and DSWPD ...
About this study. The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in ...
... assay for the detection of mutations associated with uveal melanoma. The performance characteristics of the ddPCR assay for the detection of ctDNA mutation ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.